A study published in the British Journal of Pharmacology on 3 March, led by University of Queensland researchers Associate Professor Trent Woodruff and Dr John Lee, has found the drug “PMX205” extends the life of mice that have a SOD1 mutation, when administered before or during very early disease onset. More studies are now underway to determine the safety of PMX205 before it can be tested in humans. 'Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis' tttp://onlinelibrary.wiley.com/doi/10.1111/bph.13730/full
Postive results for PMX205 in mice with SOD1 mutation
Latest News
Christmas for MND Carers: Expectation versus Reality
For many people, Christmas is a special time of year spent with family and friends. It is a time for celebrating, sharing gifts, enjoying food, taking...
Top 5 Frequently Asked Questions from October 2026
A diagnosis of Motor Neurone Disease (MND) can raise many questions for the person receiving the diagnosis as well as their family, friends and suppor...
Truflo Pumps raises $5,300 for MND NSW
For the third year running, the team at Truflo Pumps has rallied behind MND NSW, raising $5,300 through its annual MND raffle, held in memory of Gavin...
Thank You Blackshaw Belconnen
Recently Blackshaw Belconnen held their annual Charity Bowls Day, this year choosing to support MND NSW after their team member Elin sadly had a famil...